Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies

Cancer Treatment Reviews

Volumn 41, Issue 6, 2015, Pages 554-567

  Zhong, Shanliang ^a   Zhang, Xiaohui ^a   Chen, Lin ^b   Ma, Tengfei ^a   Tang, Jinhai ^a   Zhao, Jianhua ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Neoplasm; Outcome; Prognosis; Survival; Tumor

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BREAST CANCER; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; CASE CONTROL STUDY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COLORECTAL CANCER; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; DRUG USE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; DOSE RESPONSE; FEMALE; MALE; MORTALITY; NEOPLASM;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASMS;

EID: 84937641883     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.04.005     Document Type: Review

References (73)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation 2000, 101:207-213.
3. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005, 19:117-125.
4. Krens L.L., Simkens L.H., Baas J.M., Koomen E.R., Gelderblom H., Punt C.J., et al. Statin use is not associated with improved progression free survival in cetuximab treated kras mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS ONE 2014, 9:e112201.
5. Cardwell C.R., Hicks B.M., Hughes C., Murray L.J. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 2015, 26:68-78.
6. Livingstone E., Hollestein L.M., van Herk-Sukel M.P., van de Poll-Franse L., Joosse A., Schilling B., et al. Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study. Cancer Med 2014, 3:1284-1293.
7. Nam D.H., Lee H., Park J.C., Shin S.K., Lee S.K., Hyung W.J., et al. Long-term statin therapy improves oncological outcome after radical gastrectomy for stage II and III gastric cancer. Anticancer Res 2014, 34:355-361.
8. Kaffenberger S.D., Lin-Tsai O., Stratton K.L., Morgan T.M., Barocas D.A., Chang S.S., et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol 2014, 33(21):e11-e17.
9. Murtola T.J., Visvanathan K., Artama M., Vainio H., Pukkala E. Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS ONE 2014, 9:e110231.
10. Chae Y.K., Valsecchi M.E., Kim J., Bianchi A.L., Khemasuwan D., Desai A., et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011, 29:585-593.
11. Brewer T.M., Masuda H., Liu D.D., Shen Y., Liu P., Iwamoto T., et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 2013, 109:318-324.
12. Desai P., Lehman A., Chlebowski R.T., Kwan M.L., Arun M., Manson J.E., et al. Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control 2015.
13. Yu O., Eberg M., Benayoun S., Aprikian A., Batist G., Suissa S., et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2014, 32:5-11.
14. Geybels M.S., Wright J.L., Holt S.K., Kolb S., Feng Z., Stanford J.L. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 2013, 73:1214-1222.
15. Marcella S.W., David A., Ohman-Strickland P.A., Carson J., Rhoads G.G. Statin use and fatal prostate cancer: a matched case-control study. Cancer 2012, 118:4046-4052.
16. Katz M.S., Carroll P.R., Cowan J.E., Chan J.M., D'Amico A.V. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010, 106:627-632.
17. Caon J., Paquette M., Hamm J., Pickles T. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?. Prostate Cancer 2014, 2014:184297.
18. Grytli H.H., Fagerland M.W., Fossa S.D., Tasken K.A. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014, 65:635-641.
19. Habis M., Wroblewski K., Bradaric M., Ismail N., Yamada S.D., Litchfield L., et al. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS ONE 2014, 9:e104521.
20. Lavie O., Pinchev M., Rennert H.S., Segev Y., Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 2013, 130:615-619.
21. Elmore R.G., Ioffe Y., Scoles D.R., Karlan B.Y., Li A.J. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008, 111:102-105.
22. Nowakowski G.S., Maurer M.J., Habermann T.M., Ansell S.M., Macon W.R., Ristow K.M., et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010, 28:412-417.
23. Samaras P., Heider H., Haile S.R., Petrausch U., Schaefer N.G., Siciliano R.D., et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010, 89:783-787.
24. Hamilton R.J., Morilla D., Cabrera F., Leapman M., Chen L.Y., Bernstein M., et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 2014, 191:914-919.
25. Viers B.R., Houston Thompson R., Psutka S.P., Lohse C.M., Cheville J.C., Leibovich B.C., et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urol Oncol 2015.
26. Cardwell C.R., Hicks B.M., Hughes C., Murray L.J. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 2014, 32:3177-3183.
27. Lakha F., Theodoratou E., Farrington S.M., Tenesa A., Cetnarskyj R., Din F.V., et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer 2012, 12:487.
28. Ng K., Ogino S., Meyerhardt J.A., Chan J.A., Chan A.T., Niedzwiecki D., et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011, 103:1540-1551.
29. Siddiqui A.A., Nazario H., Mahgoub A., Patel M., Cipher D., Spechler S.J. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 2009, 54:1307-1311.
30. Mace A.G., Gantt G.A., Skacel M., Pai R., Hammel J.P., Kalady M.F. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 2013, 56:1217-1227.
31. Shao Y.Y., Hsu C.H., Yeh K.H., Chen H.M., Yeh Y.C., Lai C.L., et al. Statin use is associated with improved prognosis of colorectal cancer in Taiwan. Clin Colorectal Cancer 2015.
32. Hoffmeister M., Jansen L., Rudolph A., Toth C., Kloor M., Roth W., et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst 2015, 107.
33. Graf H., Jungst C., Straub G., Dogan S., Hoffmann R.T., Jakobs T., et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008, 78:34-38.
34. Song M., Chung J., Lee G., Cho S., Hong J., Shin D., et al. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era. Leuk Res 2015, 39:211-215.
35. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
36. Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt. 2010.
37. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educat Behav Statistics 2005, 30:261-293.
38. Raudenbush S.W. Analyzing effect sizes: Random-effects models. The Handbook of Research Synthesis and Meta-analysis 2009, 2:295-316.
39. Riley R.D., Higgins J.P., Deeks J.J. Interpretation of random effects meta-analyses. BMJ 2011, 342:d549.
40. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
41. Hedges L.V., Pigott T.D. The power of statistical tests in meta-analysis. Psychol Methods 2001, 6:203-217.
42. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
43. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
44. Greenland S., Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992, 135:1301-1309.
45. Viechtbauer W. Conducting meta-analyses in R with the metal for package. J Stat Softw 2010, 36:1-48.
46. Crippa A., Orsini N. Dosresmeta Performing multivariate dose-response meta-analysis 2013, R Foundation for Statistical Computing, Vienna, Austria.
47. Kollmeier M.A., Katz M.S., Mak K., Yamada Y., Feder D.J., Zhang Z., et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:713-718.
48. Mehta J.L., Bursac Z., Hauer-Jensen M., Fort C., Fink L.M. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol 2006, 98:923-928.
49. Cuaron J., Pei X., Cohen G.N., Cox B.W., Yamada Y., Zelefsky M.J., et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy 2014, 14:179-184.
50. Rotta M., Storer B.E., Storb R., Martin P.J., Flowers M.E.D., Vernon M.S., et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1463-1466.
51. da Silva R.D., Xylinas E., Kluth L., Crivelli J.J., Chrystal J., Chade D., et al. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2013, 190:487-492.
52. Kaffenberger S.D., Lin-Tsai O., Stratton K.L., Morgan T.M., Barocas D.A., Chang S.S., et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol 2015, 33:21.e11-21.e17.
53. Stavrou E.P., Buckley N., Olivier J., Pearson S.A. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference An observational cohort study using data linkage. BMJ Open 2012, 2.
54. Suna S., Sakata Y., Nakatani D., Okuda K., Shimizu M., Usami M., et al. Decreased mortality associated with statin treatment in patients with acute myocardial infarction and lymphotoxin-alpha C804A polymorphism. Atherosclerosis 2013, 227:373-379.
55. Nickels S., Vrieling A., Seibold P., Heinz J., Obi N., Flesch-Janys D., et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 2013, 8:e75088.
56. Crivelli J.J., Xylinas E., Kluth L.A., da Silva R.D., Chrystal J., Novara G., et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int 2013, 112:E4-E12.
57. Eindhoven J.A., Onuma Y., Oemrawsingh R.M., Daemen J., Van Nierop J.W.I., De Jaegere P.P.T., et al. Long-term outcome after statin treatment in routine clinical practice: Results from a prospective PCI cohort study. EuroIntervention 2012, 7:1420-1427.
58. Gaist D., Hallas J., Friis S., Hansen S., Sorensen H.T. Statin use and survival following glioblastoma multiforme. Cancer Epidemiol 2014, 38:722-727.
59. Gardette V., Bongard V., Dallongeville J., Arveiler D., Bingham A., Ruidavets J.B., et al. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). Am J Cardiol 2009, 103:381-386.
60. Haukka J., Niskanen L., Partonen T., Lonnqvist J., Tiihonen J. Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Saf 2012, 21:61-69.
61. Lipworth L., Fazio S., Kabagambe E.K., Munro H.M., Nwazue V.C., Tarone R.E., et al. A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States. Clin Epidemiol 2014, 6:15-25.
62. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
63. van Gestel Y.R., Hoeks S.E., Sin D.D., Huzeir V., Stam H., Mertens F.W., et al. COPD and cancer mortality: the influence of statins. Thorax 2009, 64:963-967.
64. Xylinas E., Kluth L.A., Crivelli J.J., Rieken M., Margulis V., Seitz C., et al. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Eur Urol 2013, 63:1134-1135.
65. Yoon L.S., Goodman M.T., Rimel B., Jeon C.Y. Statin use and survival in elderly patients with endometrial cancer. Gynecol Oncol 2015.
66. Barkas F., Rizzo M., Dinicolantonio J.J., Liberopoulos E. Beyond cholesterol reduction, the pleiotropic effects of statins: Is their use in cancer prevention hype or hope?. Clin Lipidol 2013, 8:273-277.
67. Strandberg T.E., Pyorala K., Cook T.J., Wilhelmsen L., Faergeman O., Thorgeirsson G., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
68. Han J.Y., Lee S.H., Yoo N.J., Lee S.H., Moon Y.J., Yun T., et al. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011, 17:1553-1560.
69. Konings I.R., van der Gaast A., van der Wijk L.J., de Jongh F.E., Eskens F.A., Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer 2010, 46:3200-3204.
70. Hong J.Y., Nam E.M., Lee J., Park J.O., Lee S.C., Song S.Y., et al. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol 2014, 73:125-130.
71. Kim S.T., Kang J.H., Lee J., Park S.H., Park J.O., Park Y.S., et al. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer 2014, 50:2822-2830.
72. Kawata S., Yamasaki E., Nagase T., Inui Y., Ito N., Matsuda Y., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84:886-891.
73. Levesque L.E., Hanley J.A., Kezouh A., Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087.